Effects of dopaminergic treatment on inhibitory control differ across Hoehn and Yahr stages of Parkinson's disease

© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain..

Motor inhibitory control, a core component of cognitive control, is impaired in Parkinson's disease, dramatically impacting patients' abilities to implement goal-oriented adaptive strategies. A progressive loss of the midbrain's dopamine neurons characterizes Parkinson's disease and causes motor features responsive to dopaminergic treatments. Although such treatments restore motor symptoms, their impact on response inhibition is controversial. Most studies failed to show any effect of dopaminergic medicaments, although three studies found that these drugs selectively improved inhibitory control in early-stage patients. Importantly, all previous studies assessed only one domain of motor inhibition, i.e. reactive inhibition (the ability to react to a stop signal). The other domain, i.e. proactive inhibition (the ability to modulate reactive inhibition pre-emptively according to the current context), was utterly neglected. To re-examine this issue, we recruited cognitively unimpaired Parkinson's patients under dopaminergic treatment in the early (Hoehn and Yahr, 1-1.5, n = 20), intermediate (Hoehn and Yahr 2, n = 20), and moderate/advanced (Hoehn and Yahr, 2.5-3, n = 20) stages of the disease. Using a cross-sectional study design, we compared their performance on a simple reaction-time task and a stop-signal task randomly performed twice on dopaminergic medication (ON) and after medication withdrawal (OFF). Normative data were collected on 30 healthy controls. Results suggest that medication effects are stage-dependent. In Hoehn and Yahr 1-1.5 patients, drugs selectively impair reactive inhibition, leaving proactive inhibition unaffected. In the ON state, Hoehn and Yahr two patients experienced impaired proactive inhibition, whereas reactive inhibition is no longer affected, as it deteriorates even during the OFF state. By contrast, Hoehn and Yahr 2.5-3 patients exhibited less efficient reactive and proactive inhibition in the OFF state, and medication slightly improved proactive inhibition. This evidence aligns with the dopamine overdose hypothesis, indicating that drug administration may overdose intact dopamine circuitry in the earliest stages, impairing associated cognitive functions. In later stages, the progressive degeneration of dopaminergic neurons prevents the overdose and can exert some beneficial effects. Thus, our findings suggest that inhibitory control assessment might help tailor pharmacological therapy across the disease stage to enhance Parkinson's disease patients' quality of life by minimizing the hampering of inhibitory control and maximizing the reduction of motor symptoms.

Medienart:	E-Artikel

Erscheinungsjahr:	2024
Erschienen:	2024

Enthalten in:	Zur Gesamtaufnahme - volume:6
Enthalten in:	Brain communications - 6(2024), 1 vom: 26., Seite fcad350

Sprache:	Englisch

Beteiligte Personen:	Mirabella, Giovanni [VerfasserIn] Pilotto, Andrea [VerfasserIn] Rizzardi, Andrea [VerfasserIn] Montalti, Martina [VerfasserIn] Olivola, Enrica [VerfasserIn] Zatti, Cinzia [VerfasserIn] Di Caprio, Veronica [VerfasserIn] Ferrari, Elisabetta [VerfasserIn] Modugno, Nicola [VerfasserIn] Padovani, Alessandro [VerfasserIn]

Links:	Volltext

Themen:	Dopaminergic medication Journal Article Overdose dopamine hypothesis Parkinson’s disease Proactive inhibition Reactive inhibition

Anmerkungen:	Date Revised 03.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE

doi:	10.1093/braincomms/fcad350

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM366535390